YCBD
Cbdmd Inc
AMEX · Pharmaceuticals
$0.92
-0.02 (-2.21%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.88M | 3.60M | 4.26M |
| Net Income | 504.3K | 438.1K | 574.3K |
| EPS | — | — | — |
| Profit Margin | 13.0% | 12.2% | 13.5% |
| Rev Growth | +19.6% | +16.0% | +23.9% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 3.38M | 2.68M | 3.44M |
| Total Equity | 4.40M | 4.26M | 4.18M |
| D/E Ratio | 0.77 | 0.63 | 0.82 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 851.8K | 810.0K | 832.9K |
| Free Cash Flow | 419.4K | 302.1K | 332.0K |